Abstract:Tamoxifen (TAM) resistance is a substantial challenge in the treatment of estrogen receptor (ER)-positive breast cancer. Previous studies have revealed an important role of microRNA (miRNA/miR)-26a in TAM resistance in breast cancer. However, the mechanism underlying the regulatory effects of miR-26a on TAM resistance remains to be elucidated. The expression levels of miR-26a in ER-positive breast cancer were detected by reverse transcription-quantitative polymerase chain reaction. E2F transcription factor 7 (E2F7) and MYC proto-oncogene, bHLH transcription factor (MYC) levels were detected by western blotting. The present study demonstrated that miR-26a expression was reduced in ER-positive breast cancer compared with in normal breast tissues, whereas E2F7 expression was significantly elevated. Furthermore, an inverse correlation between miR-26a and E2F7 expression was detected in ER-positive breast cancer. The results indicated that miR-26a directly inhibited E2F7 expression through translational inhibition and indirectly inhibited MYC expression partly via E2F7 repression. E2F7, in turn, decreased miR-26a expression via MYC-induced transcriptional inhibition of miRNAs. Furthermore, transfection with miR-26a mimics increased the expression of its host genes (CTD small phosphatase like and CTD small phosphatase 2), whereas ectopic E2F7 expression abrogated the effects of miR-26a. These findings indicated that miR-26a and E2F7 may form a double-negative feedback loop, resulting in downregulation of miR-26a and upregulation of E2F7 in ER-positive breast cancer. Both miR-26a knockdown and E2F7 overexpression conferred resistance to TAM in MCF-7 cells. Conversely, miR-26a overexpression and E2F7 silencing resensitized MCF-7 resistant cells to TAM. These findings revealed that a feedback loop between miR-26a and E2F7 may promote TAM resistance in ER-positive breast cancer.

Tamoxifen Represses Mir-200 Micrornas and Promotes Epithelial-to-mesenchymal Transition by Up-Regulating C-Myc in Endometrial Carcinoma Cell Lines.

miR-200a-3p promotes the malignancy of endometrial carcinoma through negative regulation of epithelial-mesenchymal transition

Tamoxifen activates Nrf2-dependent SQSTM1 transcription to promote endometrial hyperplasia.

Hypomethylation Associated Enhanced Transcription of Trefoil Factor-3 Mediates Tamoxifen-Stimulated Oncogenicity of ER+ Endometrial Carcinoma Cells

The role of miR-34c-5p/Notch in epithelial-mesenchymal transition (EMT) in endometriosis

MCAM/CD146 Promotes Tamoxifen Resistance in Breast Cancer Cells Through Induction of Epithelial–mesenchymal Transition, Decreased ERα Expression and AKT Activation

MiR-192-5p-Modified Tumor-Associated Macrophages-Derived Exosome Suppressed Endometrial Cancer Progression Through Targeting IRAK1/NF-κB Signaling

microRNA-30c negatively regulates endometrial cancer cells by targeting metastasis-associated gene-1.

Induced Tamoxifen Resistance is Mediated by Increased Methylation of E-Cadherin in Estrogen Receptor-Expressing Breast Cancer Cells

MicroRNA-200b is overexpressed in endometrial adenocarcinomas and enhances MMP2 activity by downregulating TIMP2 in human endometrial cancer cell line HEC-1A cells.

Methylation-associated Silencing of Mir-638 Promotes Endometrial Carcinoma Progression by Targeting MEF2C

MiR-206 Suppresses Epithelial Mesenchymal Transition by Targeting TGF-β Signaling in Estrogen Receptor Positive Breast Cancer Cells

A Mir-26A/e2f7 Feedback Loop Contributes to Tamoxifen Resistance in ER-positive Breast Cancer

The Mir-200 Family Regulates The Epithelial-Mesenchymal Transition Induced By Egf/Egfr In Anaplastic Thyroid Cancer Cells

Estrogen Regulates the Tumour Suppressor MiRNA-30c and Its Target Gene, MTA-1, in Endometrial Cancer

MicroRNA-182 Promotes Tumor Cell Growth by Targeting Transcription Elongation Factor A-like 7 in Endometrial Carcinoma

MicroRNA-200c overexpression inhibits tumorigenicity and metastasis of CD117+CD44+ ovarian cancer stem cells by regulating epithelial-mesenchymal transition

MiR-200c Suppresses TGF-β Signaling and Counteracts Trastuzumab Resistance and Metastasis by Targeting ZNF217 and ZEB1 in Breast Cancer

Autocrine Motility Factor Promotes Epithelial-Mesenchymal Transition in Endometrial Cancer Via MAPK Signaling Pathway.

Clinicopathological and molecular pathological characteristics in tamoxifen‑related endometrial cancer

Disrupting MALAT1/miR-200c Sponge Decreases Invasion and Migration in Endometrioid Endometrial Carcinoma.